|Mr. Blake Wise||CEO, Principal Financial Officer, Principal Accounting Officer & Director||600.75k||N/A||1971|
|Mr. Gary Loeb||Gen. Counsel, Corp. Sec. & Chief Compliance Officer||458k||N/A||1970|
|Ms. Elizabeth Bhatt||Chief Bus. Officer & COO||N/A||N/A||1969|
|Ms. Jeannie Lloyds||VP of Sales||N/A||N/A||N/A|
|Ms. Janet Dorling||Chief Commercial Officer||N/A||N/A||N/A|
Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Achaogen, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 7.